On September 16, 2015 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective stem cell therapies for degenerative diseases and immunotherapies for cancer, reported that it would give an oral presentation to discuss Phase I clinical trial data for EGFR (HER-1)-targeted Chimeric Antigen Receptor-Modified T-Cells (CAR-T) Immunotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) and other solid tumors at the 5th World Congress on Cancer Therapy on September 28, 2015 (Press release, Cellular Biomedicine Group, SEP 16, 2015, View Source [SID:1234507486]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference: 5th World Congress on Cancer Therapy, September 28-30, 2015 Atlanta, Georgia, USA
Title: EGFR (HER-1)-targeted Chimeric Antigen Receptor-Modified T-Cells Immunotherapy for Patients with Advanced or Relapsed/Refractory Solid Tumors
Oral Presentation: Scientific Program, September 28, 2015 18:05-18:25
Location: Hilton Atlanta Airport
Presenter: Wei Dong Han, MD, PhD, Chinese PLA General Hospital
The presentation expands on the data that will be presented at the European Cancer Congress poster presentation in Vienna on September 26, and will detail PLAGH/CBMG’s Phase I clinical trial data using Chimeric Antigen Receptor-Modified T-Cells (CAR-T) targeting EGFR (HER-1) for the treatment of patients with EGFR (HER-1) expressing advanced relapsed/refractory Non-Small Cell Lung Cancer (NSCLC) as well as other EGFR (HER-1) expressing solid tumors. The CAR-T trial was designed and conducted by Chinese PLA General Hospital ("PLAGH", Beijing, also known as "301 Hospital"), led by Principal Investigator Wei Dong Han, MD, PhD, head of PLAGH’s cancer immunotherapy department. Dr. Han and his research team have authored several CAR-T publications, including "Tolerance and Efficacy of Autologous or Donor-derived T-Cells Expressing CD19 Chimeric Antigen Receptors in Adult B-ALL with Extramedullary Leukemia" and "Effective Response and Delayed Toxicities of Refractory Advanced Diffused Large B-cell Lymphoma Treated by CD20-directed Chimeric Antigen Receptor-modified T-cells". (OncoImmunology (Impact Factor: 6.28). 03/2015; DOI: 10.1080/2162402X.2015.1027469 and Clin Immunol. 2014 Dec;155(2):160-75. doi: 10.1016/j.clim.2014.10.002) The Company previously announced positive clinical data from its Phase I clinical trials using CAR-T constructs against CD19, CD20 and CD30 for late-stage blood cancers.
Company management will attend the conference and be available for discussions. Full detail of the presented data will be available on the Company website following the presentation.